PYXS biotech catalysts & pipeline

PYXIS ONCOLOGY INC · Data as of 2026-10-25

Upcoming catalysts

MICVO (micvotabart pelidotin) — Initial data

Fall 2026

Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap

Source filing

MICVO (micvotabart pelidotin) — Interim data

Q4 2026

Pyxis Oncology expects to report updated data from the ongoing Phase 1/2 combination dose escalation study of MICVO and Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for 1L R/M HNSCC patients in the fourth quarter of 2026.

Source filing

MICVO (micvotabart pelidotin) — Interim data

H1 2027

Updated overall survival data from the MICVO monotherapy study are expected in the first half of 2027.

Source filing

MICVO (micvotabart pelidotin) — FDA meeting

Q1 2027

An End of Phase 2 meeting with the FDA to align on dose selection is anticipated in the first quarter of 2027.

Source filing

MICVO (micvotabart pelidotin) — Clinical data readout

H2 2027

Additional data evaluating initial durability and selection of the recommended Phase 3 dose (RP3D) for the 1L combination are expected in the second half of 2027.

Source filing

Explore the free biotech catalyst calendar